Search research articles
Contact Us
Filters
Showing results (11-20 of 52) with videos related to
Page
of 6
Sort By:
Pharmacotherapy
|
October 23, 2002
Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk
Jim Koeller, Robert L Talbert
Pharmacotherapy
|
January 17, 2002
A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure
Surakit Nathisuwan, Robert L Talbert
Journal of Cardiovascular Pharmacology and Therapeutics
|
August 17, 2004
Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial
Jerry L Bauman, Robert L Talbert
Expert Opinion on Drug Safety
|
April 10, 2010
Proton pump inhibitors and clopidogrel: is it a significant drug interaction?
Ola O Oyetayo, Robert L Talbert
Pharmacotherapy
|
July 12, 2005
Aspirin resistance: an evaluation of current evidence and measurement methods
Christopher P Martin, Robert L Talbert
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
March 20, 2015
Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism
Hayley Gray, Jennifer Seltzer, Robert L Talbert
The Journal of Urology
|
April 12, 2005
Re: transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea
Robert L Talbert, W Jerry Easterling, William Fitch
Pharmacotherapy
|
June 29, 2006
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction
Matthew K Ito, Robert L Talbert, Sotirios Tsimikas
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
August 7, 2003
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies
Robert L Talbert, John A Pieper, Matthew K Ito, et al.
Journal of Managed Care Pharmacy : JMCP
|
November 7, 2009
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting
Mark J Cziraky, Karol E Watson, Robert L Talbert
Page
of 6
Search research articles
Search
Showing results (11-20 of 52) with videos related to
Sort By:
Page
of 6
Pharmacotherapy
|
October 23, 2002
Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk
Jim Koeller, Robert L Talbert
Pharmacotherapy
|
January 17, 2002
A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure
Surakit Nathisuwan, Robert L Talbert
Journal of Cardiovascular Pharmacology and Therapeutics
|
August 17, 2004
Pharmacodynamics of beta-blockers in heart failure: lessons from the carvedilol or metoprolol European trial
Jerry L Bauman, Robert L Talbert
Expert Opinion on Drug Safety
|
April 10, 2010
Proton pump inhibitors and clopidogrel: is it a significant drug interaction?
Ola O Oyetayo, Robert L Talbert
Pharmacotherapy
|
July 12, 2005
Aspirin resistance: an evaluation of current evidence and measurement methods
Christopher P Martin, Robert L Talbert
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
March 20, 2015
Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism
Hayley Gray, Jennifer Seltzer, Robert L Talbert
The Journal of Urology
|
April 12, 2005
Re: transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea
Robert L Talbert, W Jerry Easterling, William Fitch
Pharmacotherapy
|
June 29, 2006
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction
Matthew K Ito, Robert L Talbert, Sotirios Tsimikas
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|
August 7, 2003
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies
Robert L Talbert, John A Pieper, Matthew K Ito, et al.
Journal of Managed Care Pharmacy : JMCP
|
November 7, 2009
Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting
Mark J Cziraky, Karol E Watson, Robert L Talbert
Page
of 6